Interprofessional Viewpoints on In-hospital Hyperkalemia Management: Improving Patient Outcomes in Acute Care Settings with Novel Potassium Binders
This session will provide expert guidance across the totality of the hyperkalemia management paradigm, starting with a review of the calculus as a whole, then focusing specifically on acute care settings, with emphasis on emerging clinical trial evidence and practical pearls for implementing novel potassium binders into hospital-based care.
- Appraise key mechanisms of potassium homeostasis and review patient-centric risk factors for hyperkalemia.
- Discuss the prevalence and clinical gravity of hyperkalemia, with emphasis on acute care challenges and the morbidity/mortality impact of suboptimal renin-angiotensin-aldosterone system inhibitor (RAASi) utilization in the chronic setting.
- Evaluate novel K+ binder (patiromer and sodium zirconium cyclosilicate [SZC]) pharmacology, safety and efficacy profiles, and differential clinical utility across the hyperkalemia treatment continuum.
- Examine evolving clinical trial data in support of patiromer and SZC for hyperkalemia management, with a particular focus on usage in acute care and in-hospital settings.
- Use a case-based approach to design treatment strategies using novel K+ binders that the interprofessional care team can employ to improve hyperkalemia outcomes in the hospital.
5 mins - Welcome and Introductions/Pre-test
10 mins - Elemental Foundations: An Overview of Hyperkalemia Pathophysiology, Risk Factors, and the Clinical Impact of K+
25 mins - Emerging Evidence, Evolving Paradigm: The Expanding Role of Novel K+ Binders in the Acute Care Setting
15 mins - Managing Hyperkalemia in the Hospital: Interprofessional Approaches to Outcomes Optimization with Novel Agents
5 mins - Conversations with the Experts and Q&A/Post-test
Katherine E. Di Palo, PharmD, MBA, MS
Transitional Care Excellence
Department of Medicine
Montefiore Medical Center
The University Hospital for Albert Einstein College of Medicine
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Lisa Koester-Wiedemann, ANP, CNN-NP–has no relevant financial relationships to disclose in relation to the content of this activity.
Katherine E. Di Palo, PharmD, MBA, MS–has disclosed that she receives grant/research support from Vifor Pharma.
Katherine Lee, PharmD, MPH–has no relevant financial relationships to disclose in relation to the content of this activity.
Erin Spencer, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1 hour of Interprofessional Continuing Education (IPCE) credit for learning and change.
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-23-002-L01-P)
This activity is designated for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 IPCE
- 1.00 Participation